ArticleCureus2025
Hepatotoxicity From Disease-Modifying Anti-rheumatic Drugs (DMARDs) and Association With Metabolic Syndrome in Rheumatoid Arthritis.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesHepatotoxicity is a frequent reason why disease-modifying anti-rheumatic drugs (DMARDs) are stopped or changed. We hypothesize that features of metabolic syndrome (such as obesity, dyslipidemia, and diabetes) are risk factors for hepatotoxicity leading to DMARD change in rheumatoid arthritis (RA).
methodsWe conducted a retrospective chart review of 361 patients with RA. Demographic information, lipid panels, smoking status, prior alcohol use, BMI, statin use, seropositive status, viral hepatitis serologies, and type of DMARD use were noted at the initial visit and at the time of DMARD change due to hepatotoxicity if applicable. Using exact logistic regression, odds ratios for the risk factors of DMARD change due to hepatotoxicity (primary outcome) were calculated.
resultsTwenty out of 361 patients with RA had their DMARD changed due to hepatotoxicity. Methotrexate (odds ratio {OR} 3.07) and leflunomide (OR 6.11) carried the highest OR for DMARD change. BMI > 35 (OR 2.14), diabetes mellitus II (OR 2.01), and alcohol abuse (OR 3.5) were associated with DMARD change due to hepatotoxicity but were not statistically significant. Rheumatoid factor or anti-CCP seropositivity did not appear to be associated with increased risk for the primary outcome.
conclusionOur study does suggest that several surrogates of metabolic syndrome may be associated with the risk of hepatotoxicity due to methotrexate and leflunomide. Though the study was underpowered to assess the risk for glycated hemoglobin (HbA1c) and obesity, these variables did trend toward increasing the risk. Clinicians should consider features of metabolic syndrome as potential risk factors for hepatotoxicity with DMARD use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.